Juri Hodisch

Open-Label Two-Dose Pilot Study of Landiolol for the Treatment of Atrial Fibrillation/Atrial Flutter in Caucasian Patients.

M. Wolzt, H. Domanovits, G. Stix, 2019, Circulation journal : official journal of the Japanese Circulation Society.

Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol

I. Ulč, G. Krumpl, P. Kadlecová, 2020, Cureus.

Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group

I. Ulč, G. Krumpl, P. Kadlecová, 2017, European Journal of Clinical Pharmacology.

Pharmacodynamic and -kinetic Behavior of Low-, Intermediate-, and High-Dose Landiolol During Long-Term Infusion in Whites

G. Maurer, I. Ulč, G. Krumpl, 2017, Journal of cardiovascular pharmacology.

A phase III randomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – the TEAM‐ET 2·0 trial

C. Klade, H. Gisslinger, N. Tzvetkov, 2019, British journal of haematology.

Blood Pressure Recovery After Dobutamine Antagonism: Partial With Landiolol, None With Esmolol

I. Ulč, G. Krumpl, P. Kadlecová, 2021, Clinical pharmacology in drug development.

Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group.

I. Ulč, G. Krumpl, P. Kadlecová, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Pharmacodynamic and pharmacokinetic behavior of landiolol during dobutamine challenge in healthy adults

I. Ulč, G. Krumpl, P. Kadlecová, 2020, BMC pharmacology & toxicology.

Pharmacokinetics and Pharmacodynamics of Low-, Intermediate-, and High-Dose Landiolol and Esmolol During Long-Term Infusion in Healthy Whites

G. Maurer, I. Ulč, G. Krumpl, 2017, Journal of cardiovascular pharmacology.